View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 29, 2020

Novartis to trial canakinumab to treat Covid-19 pneumonia

Novartis has plans to conduct a Phase III clinical trial to assess canakinumab (Ilaris) for the treatment of patients suffering from Covid-19 pneumonia.

Novartis has plans to conduct a Phase III clinical trial to assess canakinumab (Ilaris) for the treatment of patients suffering from Covid-19 pneumonia.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis.

The new Phase III trial, called CAN-COVID, will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

CRS is known to cause life-threatening complications in these patients.

The study is said to be based on early findings from lab tests of Covid-19 patients who had elevated IL-1β levels, among other cytokines.

Novartis intends to recruit 450 participants at various medical centres in France, Germany, Italy, Spain, the UK and the US.

Participants will be given canakinumab or placebo along with standard of care (SoC).

The primary objective of the trial is the benefit of canakinumab plus SoC in improving the chance of survival without requiring invasive mechanical ventilation in patients with Covid-19 pneumonia.

Top-line data from CAN-COVID are expected to be available later this year.

Novartis said in a statement: “This trial initiation is part of the overall Novartis approach to applying our best science to tackling the issues related to Covid-19 and further underscores Novartis commitment to quickly deploy R&D resources, medicines, clinical expertise and philanthropic aid to combat Covid-19.”

Canakinumab is the third drug candidate to be studied by the company for Covid-19 treatment.

Novartis, in alliance with Incyte, is assessing Jakavi (ruxolitinib) in a Phase III trial to treat cytokine storm in patients with severe Covid-19 pneumonia.

In addition, Novartis entered an agreement with the US Food and Drug Administration (FDA) to conduct a Phase III trial of hydroxychloroquine to treat hospitalised Covid-19 patients.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena